Company profile
BioComo company profile
BioComo develops next-generation vaccines using its proprietary BC-PIV viral vector platform. This technology combines the high cell adhesion properties of live viruses with the safety of inactivated viruses, enabling effective delivery of antigens for infectious diseases and cancer. It advances intranasal vaccines, including candidates for RSV and COVID-19, collaborating with institutions like Mie University and TFBS Bioscience.
Business identity
- Website
- https://biocomo.jp/
- Contact email
- [email protected]
- Phone number
- +81 059-392-7333
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 1-10 employees
- Founded
- 2008-05-30
Headquarters
- Headquarters
- Cassina Fra Martino, Lombardy, Italy
- Postal code
- 510-1233
- Country code
- IT
- Continent
- Europe